1.31
+0.04(+3.15%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.27 |
| Day High | 1.32 |
| Day Low | 1.21 |
| 52-Week High | 2.68 |
| 52-Week Low | 1 |
| Volume | 2.72M |
| Average Volume | 1.8M |
| Market Cap | 206.9M |
| PE | -14.56 |
| EPS | -0.09 |
| Moving Average 50 Days | 1.2 |
| Moving Average 200 Days | 1.73 |
| Change | 0.04 |
If you invested $1000 in Heron Therapeutics, Inc. (HRTX) 10 years ago, it would be worth $46.37 as of December 04, 2025 at a share price of $1.31. Whereas If you bought $1000 worth of Heron Therapeutics, Inc. (HRTX) shares 5 years ago, it would be worth $74.56 as of December 04, 2025 at a share price of $1.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
GlobeNewswire Inc.
Yesterday at 1:15 PM GMT
APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or adde
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
GlobeNewswire Inc.
Oct 29, 2025 9:58 PM GMT
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has e
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
GlobeNewswire Inc.
Oct 21, 2025 8:20 PM GMT
CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, No